[go: up one dir, main page]

WO1996028151A3 - Utilisation d'un activateur de la pyruvate dehydrogenase pour le traitement de l'ischemie dans les membres - Google Patents

Utilisation d'un activateur de la pyruvate dehydrogenase pour le traitement de l'ischemie dans les membres Download PDF

Info

Publication number
WO1996028151A3
WO1996028151A3 PCT/GB1996/000555 GB9600555W WO9628151A3 WO 1996028151 A3 WO1996028151 A3 WO 1996028151A3 GB 9600555 W GB9600555 W GB 9600555W WO 9628151 A3 WO9628151 A3 WO 9628151A3
Authority
WO
WIPO (PCT)
Prior art keywords
ischaemia
limbs
treatment
pyruvate dehydrogenase
dehydrogenase activator
Prior art date
Application number
PCT/GB1996/000555
Other languages
English (en)
Other versions
WO1996028151A2 (fr
Inventor
Dumitru Constantin-Teodosiu
James Archibald Timmons
Paul Leonard Greenhaff
Simon Martin Poucher
Original Assignee
Zeneca Ltd
Constantin Teodosiu Dumitru
James Archibald Timmons
Paul Leonard Greenhaff
Simon Martin Poucher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd, Constantin Teodosiu Dumitru, James Archibald Timmons, Paul Leonard Greenhaff, Simon Martin Poucher filed Critical Zeneca Ltd
Priority to DE69629282T priority Critical patent/DE69629282T2/de
Priority to AU49502/96A priority patent/AU4950296A/en
Priority to AT96905942T priority patent/ATE245980T1/de
Priority to JP8527370A priority patent/JPH11501653A/ja
Priority to EP96905942A priority patent/EP0814801B1/fr
Publication of WO1996028151A2 publication Critical patent/WO1996028151A2/fr
Publication of WO1996028151A3 publication Critical patent/WO1996028151A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

On décrit des agents qui inhibent la pyruvate déhydrogénase (PDH) kinase, tels que l'acide dichloroacétique, les sels et dérivés de celui-ci, lesquels sont utiles dans le traitement de l'ischémie dans les membres. L'acide dichloroacétique ainsi que ses sels sont notamment utiles dans le traitement de la claudication intermittente. On décrit également des compositions pharmaceutiques.
PCT/GB1996/000555 1995-03-14 1996-03-11 Utilisation d'un activateur de la pyruvate dehydrogenase pour le traitement de l'ischemie dans les membres WO1996028151A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69629282T DE69629282T2 (de) 1995-03-14 1996-03-11 Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern
AU49502/96A AU4950296A (en) 1995-03-14 1996-03-11 Use of a pyruvate dehydrogenase activator for the treatment of ischaemia in limbs
AT96905942T ATE245980T1 (de) 1995-03-14 1996-03-11 Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern
JP8527370A JPH11501653A (ja) 1995-03-14 1996-03-11 四肢における虚血の治療のためのピルベートデヒドロゲナーゼ活性化剤の使用
EP96905942A EP0814801B1 (fr) 1995-03-14 1996-03-11 Utilisation d'un activateur de la pyruvate dehydrogenase pour le traitement de l'ischemie dans les membres

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9505082.9 1995-03-14
GBGB9505082.9A GB9505082D0 (en) 1995-03-14 1995-03-14 Medicament

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08913324 A-371-Of-International 1997-11-24
US10/024,476 Continuation US20030013764A1 (en) 1995-03-14 2001-12-21 Use for a pyruvate dehydrogenase activator for the treatment of ischaemia in limbs

Publications (2)

Publication Number Publication Date
WO1996028151A2 WO1996028151A2 (fr) 1996-09-19
WO1996028151A3 true WO1996028151A3 (fr) 1997-01-23

Family

ID=10771147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/000555 WO1996028151A2 (fr) 1995-03-14 1996-03-11 Utilisation d'un activateur de la pyruvate dehydrogenase pour le traitement de l'ischemie dans les membres

Country Status (7)

Country Link
EP (1) EP0814801B1 (fr)
JP (1) JPH11501653A (fr)
AT (1) ATE245980T1 (fr)
AU (1) AU4950296A (fr)
DE (1) DE69629282T2 (fr)
GB (1) GB9505082D0 (fr)
WO (1) WO1996028151A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
GB9811932D0 (en) * 1998-06-04 1998-07-29 Zeneca Ltd Chemical compunds
DE60031699T2 (de) 1999-09-04 2007-08-30 Astrazeneca Ab Hydroxyacetamidobenzolsulfonamidderivate
US6878712B1 (en) 1999-09-04 2005-04-12 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
HUP0202725A3 (en) 1999-09-04 2005-04-28 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity, process for their preparation and pharmaceutical compositions containing them
KR102739453B1 (ko) 2018-11-14 2024-12-09 (주)아모레퍼시픽 피부 노화 모델의 제조방법, 그 방법에 의해 제조된 피부 노화 모델 및 그 피부 노화 모델을 이용한 항노화 물질의 스크리닝 방법

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CARRARO, F.: "Effect of dichloroacetate on lactate concentration in exercising humans", J. APPL. PHYSIOL., vol. 66, 1989, pages 591 - 597, XP000609079 *
CONSTANTIN-TEODOSIU, D. ET AL.: "PDC activity and acetyl group accumulation in skeletal muscle during isometric contraction", J. APPL. PHYSIOL., vol. 74, no. 4, 1993, pages 1712 - 8, XP000611603 *
CURTIS: "Regional and Systemic Oxygen delivery/Uptake Relations and Lactate Flux in Hyperdynamic, Endotoxin-treated Dogs.", AM. REV. RESPIR. DIS., vol. 145, 1992, pages 345 - 54, XP000611607 *
ESPINAL, J. ET AL.: "Inhibition of Pyruvate dehydrogenase Kinase by Halogenated Acetophenones", DRUG DEVELOPMENT RESEARCH, vol. 35, 1995, pages 130 - 136, XP000611456 *
FULLER S.J. ET AL.: "Reversible phosphorylation of pyruvate dehydrogenase in rat skeletal-muscle mitochondria.", BIOCHEM. JOURNAL, vol. 219, 1984, pages 635 - 646, XP000611687 *
GIAROLA P ET AL: "Antithrombic and antidyslipemic effects of diisopropylammonium dichloroacetate in animals and humans", FARMACO, ED. PRAT. (FRPPAO);71; VOL.26 (9); PP.544-56, UNIV. PAVIA;IST. GERONTOL. GERIATR.; PAVIA; ITALY, XP002018149 *
MATSUOKA S ET AL: "Effects of dichloroacetate on the mechanical function of the isolated ischemic heart", JPN. HEART J. (JHEJAR,00214868);87; VOL.28 (4); PP.531-7, TOKUSHIMA UNIV.;SCH. MED.; TOKUSHIMA; 770; JAPAN (JP), XP000608956 *
MCVEIGH J J ET AL: "Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts", AM. J. PHYSIOL. (AJPHAP,00029513);90; VOL.259 (4, PT. 2); PP.H1079-H1085, UNIV. ALBERTA;FAC. MED.; EDMONTON; T6G 2S2; AB; CAN. (CA), XP002018148 *
MJOES O D: "Effect of reduction of myocardial free fatty acid metabolism relative to that of glucose on the ischemic injury during experimental coronary artery occlusion in dogs", ACTA MED. SCAND., SUPPL. (AMSSAQ);76; VOL.587,; PP.29-34, UNIV. TROMSOE;INST. MED. BIOL.; TROMSOE; NORWAY, XP000608959 *
MOSELLA, G. ET AL.: "Trattamento locale di ulcere sperimentali nel coniglio(prodotte in animali normali sottoposti ad ischemia e stasi venosa locale da insufficienza arteriosa, venosa e fleboarteriosa) con un pomata contente DED e sostanze capillaro-protettrici.", GAZZ. MED. ITAL., vol. 129, no. 11, 1970, pages 464 - 471, XP000609088 *

Also Published As

Publication number Publication date
ATE245980T1 (de) 2003-08-15
AU4950296A (en) 1996-10-02
GB9505082D0 (en) 1995-05-03
DE69629282D1 (de) 2003-09-04
EP0814801B1 (fr) 2003-07-30
EP0814801A2 (fr) 1998-01-07
DE69629282T2 (de) 2004-04-22
WO1996028151A2 (fr) 1996-09-19
JPH11501653A (ja) 1999-02-09

Similar Documents

Publication Publication Date Title
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
EP0955044A3 (fr) Procédé pour empêcher la croissance bactérienne ou fongique comportant un agent complexant
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
WO2001066564A3 (fr) Inhibiteurs de gamma-sécrétase
NO20075066L (no) Farmasoytisk sammensetning som inneholder isoflavoner
ATE302588T1 (de) Dentales produkt gegen zahnstein und betreffende methode
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
TR200100610T2 (tr) Asetil L-karnitin ve alfa-lipoik asit içeren antioksidant bileşim
IL132107A0 (en) Substituted phenyl derivatives their preparation and use
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
EP0990648A4 (fr) Derives de 4-quinolinol et bactericides pour l'agriculture et l'horticulture contenant lesdits derives comme principe actif
MX9800408A (es) Sales de derivados de amidina y de inhibidor de ciclooxigenasa, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
AU7961900A (en) Skin texture-improving agents
MX9700470A (es) Uso de triacetato de glicerilo para tratar onicomicosis.
WO1996028151A3 (fr) Utilisation d'un activateur de la pyruvate dehydrogenase pour le traitement de l'ischemie dans les membres
CA2152998A1 (fr) Composition pharmaceutique anti-hyperglycemique
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
EP0870502A3 (fr) Utilisation d'inhibiteurs de l'assimilation d'adénosine pour la fabrication d'un médicament pour le traitement de la pancréatite
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
AU2566101A (en) Compounds and methods for the treatment of pain
AU7425394A (en) Solid, dry, chlorine-free antimicrobial compositions
AU5260096A (en) Novel pyridonecarboxylic acid derivatives or salts thereof and antibacterial agent containing the same as active ingredient
AU7911000A (en) Retard form containing alpha-lipoic acid (derivatives)
AU2811400A (en) Stable formulation containing fumagillin
AU6970394A (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

WWE Wipo information: entry into national phase

Ref document number: 1996905942

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 527370

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 913324

Date of ref document: 19971124

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996905942

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1996905942

Country of ref document: EP